Healthcare Equipment and Supplies
Company Overview of ConforMIS, Inc.
ConforMIS, Inc., a medical technology company, develops, manufactures, and sells customized joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iUni G2, a unicompartmental product for treatment of the medial or lateral compartment of the knee; and iDuo G2, a bicompartmental partial implant for patients with osteoarthritis of the patellofemoral compartment of the knee and either the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments. It is also developing iTotal Hip, a customized...
28 Crosby Drive
Bedford, MA 01730
Founded in 2004
Key Executives for ConforMIS, Inc.
Founder, Chief Executive Officer, President, Director and Chairman of Asia Strategy Committee
Total Annual Compensation: $365.0K
Chief Financial Officer
Total Annual Compensation: $231.9K
Chief Technology Officer
Total Annual Compensation: $230.1K
Compensation as of Fiscal Year 2014.
ConforMIS, Inc. Key Developments
ConforMIS, Inc. Reports Un-Audited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Year 2015
Aug 11 15
ConforMIS, Inc. reported un-audited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $19.2 million compared to $11.2 million. The 2015 revenue including $3.5 million related to the settlement of patent litigation, up 72% year-over-year on a reported basis and up 81% year-over-year on a constant currency basis. Net loss was $10.9 million, or $2.51 per basic and diluted share, compared to $10.5 million, or $2.49 per basic and diluted share, for the same period last year. The company reported loss from operations of $10.9 million compared to $10.5 million and loss before income taxes of $10.9 million compared to $10.5 million for the last year.
For the six months, the company reported total revenue of $33.9 million compared to $22.0 million, net loss of $25.1 million, or $5.82 per basic and diluted share, compared to $23.2 million, or $5.52 per basic and diluted share, loss from operations of $24.9 million compared to $23.1 million and loss before income taxes of $25.1 million compared to $23.2 million for the last year.
For the full year 2015, the company expects total revenue in a range of $72 million to $74 million, representing year-over-year growth of 50% to 54% on a reported basis and 57% to 61% on a constant currency basis. The company's total revenue guidance includes approximately $3 million of currency headwind in revenue results.
ConforMIS Announces Results of Multiple Studies of its Customized Knee Replacements Presented at the 2015 Pan Pacific International Congress for Joint Reconstruction
Aug 3 15
ConforMIS, Inc. announced results from six clinical studies presented at the 2015 Pan Pacific International Congress for Joint Reconstruction (ICJR). In an ongoing, blinded, US multicenter study, the investigators reported that patients with customized ConforMIS i iTotal CR knee replacements were more likely to have an excellent or good objective Knee Society Score (KSS) and walked statistically significantly faster than patients with standard, off-the-shelf total knee replacements. For this study, researchers at seven US centers performed an interim analysis of 295 consecutively enrolled total knee replacement patients using a variety of functional tests and the KSS, a validated testing instrument used to assess patient outcomes. The objective component of the KSS measures factors such as range of motion, alignment, and stability, which are important for regaining functional abilities. Patients with iTotal CR knee replacements were 1.7 times more likely to achieve an excellent or good objective KSS, whereas patients with off-the-shelf knee replacements were 2.6 times more likely to achieve a poor objective KSS. In a separate, validated functional test administered during this study, known as the Aggregated Locomotor Function (ALF) test, blinded operators assessed patients' ability to perform various activities of daily living, including walking, standing from a chair and climbing stairs. Patients with iTotal CR knee replacements showed a statistically significantly better ALF score than patients with off-the-shelf knee replacements. In addition to achieving an overall better ALF score, the data also showed statistical significance in one individual component of the ALF test: patients with iTotal CR knee replacements walked statistically significantly faster than patients with off-the-shelf knee replacements.
ConforMIS, Inc. to Report Q2, 2015 Results on Aug 11, 2015
Jul 27 15
ConforMIS, Inc. announced that they will report Q2, 2015 results Pre-Market on Aug 11, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|